Non-Hodgkin Lymphoma
Conditions
Brief summary
Study GLB-002-01 is a first-in-human (FIH), phase 1, open-label, dose escalation and expansion clinical study, the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-002 monotherapy in participants with relapsed or refractory Non-Hodgkin lymphomas (R/R NHL).
Interventions
DRUGGLB-002
Administered orally according to the assigned treatment schedule.
Sponsors
Hangzhou GluBio Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants must understand and voluntarily sign a written informed consent form (ICF) prior to any study-related assessments/procedures being performed. * Participants is ≥18 years of age at the time of signing the ICF. * Participants with histopathologically or immunohistochemically confirmed NHL according to 2016 World Health Organization (WHO) haematolymphoid tumors criteria classification (CLL/SLL diagnosis according to 2018 IWCLL) who have failed standard of care therapy or lack an effective treatment regimen. * Participants in Phase Ib screening period with measurable lesion, but no measurable nodal lesion limit for participants in Phase Ia. * Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2. * Life expectancy \> 3 months. * Good performance of major organs, including hematology, liver and kidney function, and coagulation. etc. * Participants are willing and able to adhere to the study visit schedule and other protocol requirements.
Exclusion criteria
* Receipt of anticancer medications/therapies such as chemotherapy, targeted therapy, immunotherapy, biologic therapy, or herbal agent ≤ 28 days or 5 half-lives, whichever is shorter, prior to the first dose of GLB-002; or chimeric antigen receptor T cell therapy (CAR-T) within 3 months prior to the first dose of GLB-002. * Currently enrolled in any other investigational drug study or participation within the last 28 days or 5 half-lives, whichever is shorter, prior to the first dose of GLB-002 (exception of participants who participated in only one investigational drug study with overall survival follow-up). * Participants with unresolved clinically significant toxicities of \> Grade 1 AE or not be recovered to baseline value from prior anticancer therapies with exception of alopecia or hyperpigmentation of the skin. * Participants who are scheduled to receive other anticancer therapies or other investigational drugs during the study period. * Participants with active acute or chronic graft versus host disease (GVHD) requiring systemic immunosuppressive therapy, or participants requiring treatment with systemic corticosteroids (\>10 mg/day prednisone or equivalent) or other immunosuppressive drugs within the last 7 days prior to the first dose of GLB-002 or during the study period. * Receipt of Autologous Stem Cell Transplantation (ASCT) within the last 3 months, or allogeneic hematopoietic stem cell transplantation (allo-HSCT) within the last 6 months prior to the first dose of GLB-002. * Participants with known active leukemic involvement in central nervous system (CNS). * Participants with peripheral neuropathy ≥ Grade 2 (Graded according to CTCAE version 5.0). * History of, or current active cancer other malignancy for the past 5 years, with the exception of curatively resected cancer in situ, including cervical carcinoma in situ, basal cell carcinoma of the skin, or prostate cancer in situ, etc * QT interval interval \>470 milliseconds (ms) using electrocardiographic (ECG) at Screening. * Participants has impaired cardiac function or clinically significant cardiac disease at current or within last 6 months. * Participants with known active infection of hepatitis B virus (HBV) or hepatitis C virus C (HCV). * Participants with known human immunodeficiency virus (HIV) infection. * Participants with known life-threatening or clinical significant uncontrolled active systemic infections unrelated to malignant hematologic diseases * Participants with a condition that may affects the absorption, distribution, metabolism and excretion of GLB-002. * Medications or supplements that are known to be strong and moderate inhibitors or inducers of cytochrome P-450 isozyme (CYP)3A4/5 and/or P-glycoprotein (P-gp) within 7 days or 5 half-lives prior to the first dose of GLB-002, whichever is shorter. * Participants who have undergone major surgery within 28 days prior to the first dose of the GLB-002. * Pregnant or lactating women. * Participants who have cognitive impairment due to any psychiatric or neurological condition, including epilepsy and dementia, may limit their understanding, performance, and study compliance with the ICF. * Participants,in the opinion of the Investigator, who are unsuitable to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose-limiting Toxicity (DLT) | Up to 35 days after first dose of study treatment in Phase 1a | DLT is defined as the treatment emergent adverse events (TEAEs) meeting protocol specified DLT criteria and occurring within the DLT assessment period, except those that are clearly and incontrovertibly due to extraneous causes including disease progression, pre-existing medical condition that has not worsened from baseline, or other causes that are clearly not due to study drug. |
| Maximum Tolerated Dose (MTD) | Up to 2 years (each cycle is 28 days) | MTD is defined as the highest dose level at which no more than 1 of 6 DLT-evaluable participants experienced a DLT. |
| Recommended Expansion Doses (RED) | Up to 2 years (each cycle is 28 days) | RED will be decided by safety review committee (SRC) considering the data including safety, tolerability, PK, PD, and preliminary efficacy of GLB-002 in dose escalation. RED will be the dose level below MTD. |
| Incidence, Relatedness, Seriousness and Severity of Adverse Events (AEs) | Up to 2 years | AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. AE will be graded according to the National Cancer Institute Common Terminology Criteria for AE (NCI CTCAE) version 5.0. |
| Recommended Phase 2 Dose (RP2D) | Up to 2 years | RP2D based on the totality of data across dosing cohorts in the dose escalation and expansion phases of the study including PK, PD, safety and efficacy outcomes. |
| Objective Response Rate (ORR) | Up to 2 years | ORR is defined as the percent of participants whose best overall response is complete response (CR) or partial response (PR). CR and PR will be assessed by 2014 Lugano for NHL and/or 2018 International Working Group Criteria for Chronic Lymphocyte Leukemia (2018 IWCLL). |
| Time to Response (TTR) | Up to 2 years | For participants with objective response, TTR was defined as the time of participants from the first treatment administration to the first incidence of a confirmed CR or PR was reported. CR and PR will be assessed by 2014 Lugano for NHL and/or 2018 IWCLL. |
| Duration of Remission or Response (DOR) | Up to 2 years | For participants with objective response, DOR is measured from the time of any of CR or PR are first met (whichever is first recorded) until the first date at which progressive disease or death from any cause is objectively documented assessment. CR and PR will be assessed by 2014 Lugano for NHL and/or 2018 IWCLL. |
| Progression-free Survival (PFS) | Up to 2 years | PFS is defined as the time from the first dose of GLB-002 to the first occurrence of progressive disease (PD) or death from any cause. PD will be assessed by 2014 Lugano for NHL and/or 2018 IWCLL. |
| Overall Survival (OS) | Up to 2 years | OS is defined as the time from the first dose of GLB-002 to death due to any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-Cav,SS | Up to 2 years | Average plasma concentration at steady state |
| GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-Cmax,SS | Up to 2 years | Maximum plasma concentration at steady state |
| GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-Cmin,SS | Up to 2 years | Minimum plasma concentration at steady state |
| GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-AUC0-tau | Up to 2 years | Area under the concentration-time curve during the dosing interval |
| GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-λz | Up to 2 years | Terminal rate constant |
| GLB-002 and GLB-A062-A (R-enantiomers of GLB-002) Pharmacokinetics after Single Administration-AUC0-last | Up to 48 hours after single administration | Area under the concentration-time curve from zero to the last measurable concentration |
| GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-CLSS/F | Up to 2 years | Apparent clearance at steady state |
| GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-T1/2 | Up to 2 years | Terminal half-life |
| GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-Rac [AUC] | Up to 2 years | Accumulation index in area under the concentration-time curve |
| GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-Rac [Cmax] | Up to 2 years | Accumulation index in maximum plasma concentration |
| GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-DF | Up to 2 years | Degree of fluctuation index |
| GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-Vz/F | Up to 2 years | Apparent volume of distribution |
| GLB-002 and GLB-A062-A Pharmacokinetics after Single Administration-AUC0-24 | Up to 48 hours after single administration | Area under the concentration-time curve from 0 to 24 hours |
| GLB-002 and GLB-A062-A Pharmacokinetics after Single Administration-AUC0-inf | Up to 48 hours after single administration | Area under the concentration-time curve from 0 to infinity |
| GLB-002 and GLB-A062-A Pharmacokinetics after Single Administration-Cmax | Up to 48 hours after single administration | Maximum plasma concentration |
| GLB-002 and GLB-A062-A Pharmacokinetics after Single Administration-Tmax | Up to 48 hours after single administration | The time to reach maximum concentration |
| GLB-002 and GLB-A062-A Pharmacokinetics after Single Administration-T1/2 | Up to 48 hours after single administration | Terminal half-life |
| GLB-002 and GLB-A062-A Pharmacokinetics after Single Administration-Vz/F | Up to 48 hours after single administration | Apparent volume of distribution |
| GLB-002 and GLB-A062-A Pharmacokinetics after Single Administration-CL/F | Up to 48 hours after single administration | Apparent total clearance of the drug from plasma after oral administration |
| GLB-002 and GLB-A062-A Pharmacokinetics after Single Administration-λz | Up to 48 hours after single administration | Terminal rate constant |
| GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-Tmax,SS | Up to 2 years | Time of maximum concentration at steady state |
Countries
China
Contacts
Primary ContactJing Liu, MD
Outcome results
None listed